[Form 4] Nucor Corporation Insider Trading Activity

Rhea-AI Filing Summary

Bios Equity–affiliated funds expand their stake in Actuate Therapeutics (ACTU). On 06/27/2025, Bios 2024 Co-Invest, LP acquired 71,428 common shares at $7.00 in a private placement governed by the 25 June 2025 Securities Purchase Agreement. The fund also received cash-only warrants for an additional 71,428 shares at the same $7.00 exercise price.

Following the purchase, the wider Bios Equity group—spanning 17 limited-partnership vehicles—reports beneficial ownership of approximately 10.2 million ACTU shares, keeping the group well above the 10 % insider threshold. The warrants are immediately exercisable and will expire 20 days after the earlier of (i) the FDA granting Breakthrough Therapy designation for elraglusib or (ii) the FDA’s written guidance on Phase 2/3 registration strategy for the drug.

The filing underscores ongoing strategic and financial support from Bios Equity Partners, whose principals Aaron G.L. Fletcher and Leslie W. Kreis control the voting power of the aggregated holdings. This Form 4 is the third of three split submissions due to EDGAR’s 10-reporting-person limit.

Insights

Financial Analyst

TL;DR: Insider group adds $0.5 m in stock plus matching warrants, pushing combined stake to ~10.2 m shares—signal of continued commitment.

Transaction substance: The 71,428-share purchase equates to roughly $500 k in fresh capital. Combined with the 1:1 warrant grant, Bios Equity now owns both additional equity and optionality tied to FDA milestones for elraglusib, the company’s lead asset.

Strategic read-through: Insider buying in a private placement typically suggests confidence, particularly when tied to clinical catalysts. The cash-only warrant structure aligns Bios with shareholders because exercise requires further capital and occurs only if value creation around FDA decisions materialises.

Shareholder impact: Short-term dilution is minimal (<0.5 % of the ~10.2 m shares already controlled by Bios). Potential future dilution from warrant exercise is limited to the same 71,428 shares and would be offset by cash proceeds.

Governance considerations: With >10 % ownership and board representation, Bios maintains significant influence over strategic decisions. Investors should monitor any subsequent sales or additional private placements that could shift the ownership dynamic.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

QUERY KENNETH REX

(Last) (First) (Middle)

1915 REXFORD ROAD

(Street)

CHARLOTTE NC 28211

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NUCOR CORP [ NUE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Vice President

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/26/2025		S		2,912	D	$130.3012	101,168	D
Common Stock	06/26/2025		S		7,088	D	$130.4	94,080	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Caitlin A. Kelly, attorney-in-fact for Mr. Query	06/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Actuate Therapeutics (ACTU) shares did Bios 2024 Co-Invest buy?

71,428 common shares were purchased on 06/27/2025 at $7.00 each.

What is the size of Bios Equity’s total beneficial ownership in ACTU after the transaction?

Across 17 affiliated funds, Bios Equity reports ownership of about 10.2 million shares.

What are the key terms of the newly issued warrants?

The warrants cover 71,428 shares, carry a $7.00 exercise price, are cash-only exercisable, and expire 20 days after specified FDA milestones.

Why were three separate Form 4 filings submitted?

EDGAR limits a single Form 4 to 10 reporting persons; the insider group exceeded that number, necessitating three filings.

Does the transaction affect Bios Equity’s status as a 10 % owner?

Yes, the added shares keep Bios Equity well above the 10 % ownership threshold, maintaining insider status.